SCHEMBL13201949

SCHEMBL13201949

COc1cccc(-c2nc(N3CCOCC3)nc(Nc3cccnc3)c2COS(=O)(=O)c2ccc(C)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 8/20 0.45
▸ SRC P12931 1/20 0.43
▸ CTSL P07711 1/20 0.41
▸ CTSB P07858 1/20 0.41
▸ CTSS P25774 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ TSHR P16473 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ MTOR P42345 2/20 0.40
▸ SMG1 Q96Q15 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13219404 0.86 PIK3CA (0.51) PIK3CASRCCTSLCTSBCTSS
SCHEMBL13201952 0.84 PIK3CA (0.52) PIK3CASRCCTSLCTSBCTSS
SCHEMBL12656401 0.84 PIK3CA (0.51) PIK3CASRCCTSLCTSBCTSS
SCHEMBL1831467 0.83 PIK3CA (0.54) PIK3CASRCCTSLCTSBCTSS
SCHEMBL1845116 0.81 PIK3CA (0.51) PIK3CASRCCTSLCTSBCTSS
SCHEMBL1831465 0.80 PIK3CA (0.53) PIK3CASRCCTSLCTSBCTSS
SCHEMBL1818372 0.79 PIK3CA (0.56) PIK3CASRCCTSLCTSBCTSS
SCHEMBL13201951 0.79 PIK3CA (0.51) PIK3CASRCCTSLCTSBCTSS
SCHEMBL12656402 0.79 PIK3CA (0.48) PIK3CASRCCTSLCTSBCTSS
SCHEMBL1843086 0.79 PIK3CA (0.46) PIK3CASRCCTSLCTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2316831-B1 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer NOVARTIS AG (CH) 2013-03-06 — — EP disclosed
US-7767669-B2 Small molecule PI 3-kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-03 — — US disclosed
US-20090060912-A1 SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE CHIRON CORPORATION (US) 2009-03-05 — — US disclosed
US-7423148-B2 Small molecule PI 3-kinase inhibitors and methods of their use CHIRON CORPORATION (US) 2008-09-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060912-A1 SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE PI4KB, AKT3, PI4KA PIK3CA 8/4885SRC 330/4885CTSL 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback